B+
Bull case
25%
Probability
Target price
$40.00
+60.7% vs current
AKTS
Aktis OncologyANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$29.00
+16.5% vs current
B-
Bear case
25%
Probability
Target price
$17.00
-31.7% vs current
AI sentiment snapshot
Latest data as of 2026-07-14
Recent news sentiment (30D)
-0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+61.1
Score
AI commentary
Sentiment is mixed-to-cautious: company disclosures show meaningful clinical progress, while earnings coverage highlighted an EPS miss. Social context, insider activity, and post-print analyst revisions are unavailable, so there is no independent confirmation of a stronger near-term trend.
RankAlpha Sentiment Codex - 2026-07-14
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-31catalystQ1 earnings digestion remains a near-term overhangMedium impact
Associated Press coverage reported a $0.38 quarterly loss versus a $0.31 analyst estimate, although revenue exceeded expectations. With limited coverage, near-term sentiment may remain cautious until clinical execution reasserts itself. [#PR-EARNINGS-2026-05-12]
2026-12-31eventAKY-2519 Phase 1b expansion in 2H 2026High impact
Aktis has initiated the mCRPC Phase 1b trial and plans a second basket trial in additional solid tumors during the second half of 2026. Execution against this schedule is the key intermediate de-risking test. [#SEC-8K-2026-05-11]
2027-03-31catalystPreliminary data from both lead programs in 2027High impact
Management expects preliminary AKY-2519 data in 2027 and preliminary AKY-1189 Phase 1b data in the first quarter of 2027. These readouts are the principal longer-term value inflection points, but remain clinically uncertain. [#SEC-8K-2026-05-11] [#SEC-8K-2026-03-30]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-14 • Updated nightlySource: Internal modelMethodology